BPH Therapy Focus Urologix specializes in minimally invasive treatments for BPH using Cooled ThermoTherapy and Prostiva RF Therapy, indicating ongoing product differentiation in targeted prostate therapy that could align with hospitals, surgical centers, and urology clinics seeking proven BPH solutions.

Mid-Sized Specialized With 11-50 employees and revenue in the $10M-$25M range, Urologix sits between small startups and large medtech firms, presenting a partner profile for niche distributors and regional sales teams seeking specialty medical devices with established regulatory and clinical narratives.

Licensing Opportunity Prostiva RF Therapy is licensed from Medtronic, suggesting potential for co-marketing, co-development, or expansion of licensed therapies to additional markets or geographies through strategic partnerships.

Digital Presence Tech stack includes WordPress, Google Cloud, Cloudflare, and other web tools, indicating readiness for digital lead generation, online product education, and demand generation campaigns to capture urology clinic interest.

Growth Pathways Revenue scale and product focus on durable relief of BPH symptoms point to cross-selling opportunities with adjacent urology devices, accessories, or services, as well as potential expansion into clinics seeking proven, patient-friendly solutions with clear outcomes.